Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years.
Eric Simpson, Tilo Biedermann, Leon Kircik et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis followed patients with moderate-to-severe atopic dermatitis who responded to lebrikizumab by Week 16 in the ADvocate1&2 randomized trials and continued into the ADjoin extension. Week 16 responders were re-randomized to lebrikizumab every 2 or 4 weeks or withdrawal; the report presents as-observed outcomes through Week 104. With continued lebrikizumab, the proportions achieving complete skin clearance and minimal or no itch increased. By Week 104, approximately half of responders receiving either dosing schedule achieved IGA 0 and approximately half reported Pruritus NRS 0 or 1.
Key findings
- Among Week 16 IGA (0,1) responders, IGA 0 increased from 33.8% to 52.3% with Q2W and from 29.9% to 45.5% with Q4W.
- Among Week 16 EASI 75 responders, EASI 100 increased from 21.4% to 39.7% with Q2W and from 20.0% to 41.3% with Q4W.
- Among per-protocol responders, Pruritus NRS (0,1) increased from 35.2% to 57.4% with Q2W and from 34.2% to 55.4% with Q4W.
Why it matters
The findings suggest that early response to lebrikizumab may deepen with continued treatment, with more patients reaching complete skin clearance or minimal itch over two years. These outcomes provide longer-term information on response beyond the initial treatment period, while applying specifically to patients who had already responded by Week 16.
What to keep in mind
The analysis reports as-observed data and focuses on Week 16 responders, so findings may not represent all patients with atopic dermatitis or account for outcomes among those without an early response.